Lupus, a debilitating disease that has had pharmaceutical companies scratching their heads for years, has effected and taken many lives. Lupus is an autoimmune disease, by which the defense system against pathogens instead attacks the body’s own tissues. Generally, this disease effects women of child-bearing age, resulting in rashes, arthritis, mouth sores, kidney damage, among a number of other symptoms. Currently, there are about 325,000 Americans who suffer from the disease and are awaiting a drug to ease their pain. Fortunately, their long wait may be over.
The biotechnology company, Human Genome Sciences, announced on Monday that its experimental drug in fighting Lupus, Benlysta, has passed its second big clinical trial. This ultimately raises the chances that the drug will receive approval, and be the first new treatment released for Lupus in over forty years. While Human Genome Sciences wants to release Benlysta in the first half of 2010, the first doses will most likely go to the 200,000 Americans who are suffering the most.
While the drug did not test as well during the second trial as the first, both were sufficient enough to pass the trials. In the first test, 43.2 percent of patients who were consuming a high dosage of Benlysta showed significant signs of improvement, compared with 33.8 percent of those who were receiving a placebo. In the second study, there was not a statistically significant difference between those taking the drug, and those taking the placebo. However, the second trial took place in North America and Western Europe, while the first took place in Asia, South America, and Eastern Europe. The difference in results can be easily attributed to the lack of top-notch medical resources located in the aforementioned regions, giving more of an opporutnity for the drug to be effective to people of the first trial, rather than the second.
Human Genome Sciences has been a pioneer in genomics, which is the analyzation of human DNA. This is the same organization that discovered the gene for protein. Benlysta, would block a protein that stimulates B cells, which are consequently a part of the immune system. If this drug is approved, it would be one of the pioneer pharmaceutical drug to come from genomics.

